Levent ÖNER, Emirhan NEMUTLU, Yağmur AKDAĞ, Selma ŞAHİN

Determination of N-acetylcysteine in the presence of ciprofloxacin or levofloxacin in microparticulate dry powder inhalers

A fast and easy method was validated for simultaneous determination of ciprofloxacin hydrochloride monohydrate (CP), levofloxacin hemihydrate (LV), and N-acetylcysteine (NAC) in samples. The analysis was performed on a C18 column (250 × 4.6 mm, 5 µm) (Inertsil ODS-3V) using an isocratic elution method with a mobile phase composed of 25 mM KH2PO4 (pH 3.0) and methanol (72:28, v/v) at a flow rate of 1 mL/min. UV detection was performed at 214 nm for NAC and 293 nm for CP and LV. The method was validated for linearity, accuracy, precision (repeatability and reproducibility), specificity, sensitivity, and stability. The calibration study using several media demonstrated that the calibration curves were linear for all compounds in all media (R2 >0.9993). The limit of detection was 0.098 µg/mL for CP, 0.049 µg/mL for LV, and 0.487 µg/mL for NAC. The limit of quantification was 0.328 µg/mL for CP, 0.165 µg/mL for LV, and 1.624 µg/mL for NAC. Precision and accuracy values of the method fulfilled the required limits. All these outcomes demonstrate that the validated HPLC method is appropriate for simultaneous analysis of CP, LV, and NAC in samples for content uniformity of dry powder inhaler and permeability studies

PDF

___

1. Lay-Son G, Puga A, Astudillo P, Repetto GM; Collaborative Group of the Chilean National Cystic Fibrosis Program. Cystic fibrosis in Chilean patients: analysis of 36 common CFTR gene mutations. Journal of Cystic Fibrosis 2011; 10 (1): 66-70. doi: 10.1016/j.jcf.2010.10.002
2. van Gool K, Norman R, Delatycki MB, Hall J, Massie J. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value in Health 2013; 16 (2): 345-55. doi: 10.1016/j.jval.2012.12.003
3. Garland AL, Walton WG, Coakley RD, Tan CD, Gilmore RC et al. Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways. Proceedings of the National Academy of Sciences of the United States of America 2013; 110 (40): 15973-15978. doi: 10.1073/pnas.1311999110
4. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. American Journal of Respiratory and Critical Care Medicine 2011; 183 (11): 1463-1471. doi: 10.1164/rccm.201009-1478CI
5. Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012; 487 (7405): 109-113. doi: 10.1038/nature11130
6. Elborn JS, Henig NR. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert Opinion on Pharmacotherapy 2010; 11 (8): 1373-1385. doi: 10.1517/14656566.2010.482102
7. Cipolla D, Chan HK. Inhaled antibiotics to treat lung infection. Pharmaceutical Patent Analyst 2013; 2 (5): 647-663. doi: 10.4155/ppa.13.47
8. Buttini F, Rossi I, Di Cuia M, Rossi A, Colombo G et al. Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients. International Journal of Pharmaceutics 2016; 502 (1-2): 242-248. doi: 10.1016/j.ijpharm.2016.02.005
9. Hodson ME, Butland RJA, Roberts CM, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intravenous treatment for pseudomonas-aeruginosa infection in adults with cystic fibrosis. Lancet 1987; 1 (8527): 235-237. doi: 10.1016/S0140-6736(87)90062-6
10. Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic-fibrosis. Association of Professors of Medicine 1987; 82 (4A): 180-184.
11. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine 2011; 183 (11): 1510-1516. doi: 10.1164/rccm.201008-1293OC
12. Chamseddin C, Jira TH. Comparison of the chromatographic behavior of levofloxacin, ciprofloxacin and moxifloxacin on various HPLC phases. Die Pharmazie 2011; 66 (4): 244-248. doi: 10.1691/ph.2011.0314
13. Samanidou V, Demetriou C, Papadoyannis I. Direct determination of four fluoroquinolones, enoxacin, norfloxacin, ofloxacin, and ciprofloxacin, in pharmaceuticals and blood serum by HPLC. Analytical and Bioanalytical Chemistry 2003; 375 (5): 623-629. doi: 10.1007/s00216-003-1749-9
14. Espinosa-Mansilla A, Peña AMdl, Gómez DG, Salinas F. HPLC determination of enoxacin, ciprofloxacin, norfloxacin and ofloxacin with photoinduced fluorimetric (PIF) detection and multiemission scanning: application to urine and serum. Journal of Chromatography B 2005; 822 (1): 185-193. doi: 10.1016/j.jchromb.2005.05.045
15. Czyrski A, Szałek E. An HPLC method for levofloxacin determination and its application in biomedical analysis. Journal of Analytical Chemistry 2016; 71 (8): 840-843. doi: 10.1134/S1061934816080049
16. Siewert S. Validation of a levofloxacin HPLC assay in plasma and dialysate for pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis 2006; 41 (4): 1360-1362. doi: 10.1016/j.jpba.2006.02.010
17. Böttcher S, von Baum H, Hoppe-Tichy T, Benz C, Sonntag HG. An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum. Journal of Pharmaceutical and Biomedical Analysis 2001; 25 (2): 197-203. doi: 10.1016/S0731-7085(00)00478-7
18. Sana S, Rajania A, Sumedha N, Pravin P, Shripad N. Development and validation of RP-HPLC method for the estimation of N-acetylcysteine in wet cough syrup. International Journal of Drug Development and Research 2012; 4 (2): 284-293.
19. Tsikas D, Sandmann J, Ikic M, Fauler J, Stichtenoth DO et al. Analysis of cysteine and N-acetylcysteine in human plasma by high-performance liquid chromatography at the basal state and after oral administration of N-acetylcysteine. Journal of Chromatography B: Biomedical Sciences and Applications 1998; 708 (1): 55-60. doi: 10.1016/S0378-4347(97)00670-1
20. Ercal N, Oztezcan S, Hammond TC, Matthews RH, Spitz DR. High-performance liquid chromatography assay for N-acetylcysteine in biological samples following derivatization with N-(1-pyrenyl)maleimide. Journal of Chromatography B: Biomedical Sciences and Applications 1996; 685 (2): 329-334. doi: 10.1016/S0378-4347(96)00196-X
21. El-Feky MA, El-Rehewy MS, Hassan MA, Abolella HA, Abd El-Baky RM et al. Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces. Polish Journal of Microbiology 2009; 58 (3): 261-267.
22. Ozdil B, Kece C, Cosar A, Akkiz H, Sandikci M. Potential benefits of combined N-acetylcysteine and ciprofloxacin therapy in partial biliary obstruction. Journal of Clinical Pharmacology 2010; 50 (12): 1414-1419. doi: 10.1177/ 0091270010361257
23. Moon JH, Jang EY, Shim KS, Lee JY. In vitro effects of N-acetyl cysteine alone and in combination with antibiotics on Prevotella intermedia. Journal of Microbiology 2015; 53 (5): 321-329. doi: 10.1007/s12275-015-4500-2
24. Goswami M, Jawali N. N-Acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. Antimicrobial Agents and Chemotherapy 2010; 54 (8): 3529-3530. doi: 10.1128/AAC.00710-10
25. Landini G, Di Maggio T, Sergio F, Docquier JD, Rossolini GM et al. Effect of high N-acetylcysteine concentrations on antibiotic activity against a large collection of respiratory pathogens. Antimicrobial Agents and Chemotherapy 2016; 60 (12): 7513-7517. doi: 10.1128/AAC.01334-16
26. del Prado G, Ruiz V, Naves P, Rodríguez-Cerrato V, Soriano F et al. Biofilm formation by Streptococcus pneumoniae strains and effects of human serum albumin, ibuprofen, N-acetyl-l-cysteine, amoxicillin, erythromycin, and levofloxacin. Diagnostic Microbiology and Infectious Disease 2010; 67 (4): 311-318. doi: 10.1016/j.diagmicrobio.2010.03.016
27. ICH. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2 (R1). Geneva, Switzerland: International Conference on Harmonization, 2005.
28. Akdag Cayli Y, Sahin S, Buttini F, Balducci AG, Montanari S et al. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients. Drug Development and Industrial Pharmacy 2017; 43 (8): 1378-1389. doi: 10.1080/03639045.2017.1318902